비뇨기과 질환, 특히 신장 결석의 빈도가 증가하고 환자의 회복과 편안함을 향상시키는 최소침습적 기술의 사용이 요관 스텐트 시장을 견인하고 있습니다. Verified Market Research의 애널리스트에 따르면, 요관 스텐트 시장은 2024년 약 5억 4,854만 달러 규모에서 예측 기간 동안 8억 4,374만 달러 규모에 달할 것으로 추정됩니다.
스텐트 재료 및 디자인의 기술적 개선, 특히 유연하고 생체적합성이 높은 선택이 시장 수요를 촉진하고 있습니다. 이로 인해 시장은 2026년부터 2032년까지 6.1%의 CAGR로 성장할 것으로 예상됩니다.
요관 스텐트 시장 정의/개요
요관 스텐트는 특히 정상적인 소변의 흐름이 방해받는 경우 신장에서 방광으로 소변을 배출하는 것을 돕기 위해 요관에 삽입되는 가늘고 유연한 튜브입니다. 이 스텐트는 신장 결석, 종양이나 협착으로 인한 요관 폐색, 부종이나 조직 수복으로 인한 수술 후 폐색 치료에 널리 사용되고 있습니다. 요관 스텐트는 요관 개통을 유지하여 최적의 신장 기능을 보장하고 요로폐색에 따른 증상을 완화하는 비뇨기과 치료의 중요한 요소입니다.
신장 결석 발생 증가는 요관 스텐트 시장의 주요 촉진요인입니다. 미국 당뇨병-소화기-신장병 연구소(NIDDK)는 미국 남성의 약 11%, 여성의 약 9%가 신장 결석을 앓고 있는 것으로 추정하고 있으며, 미국 내 신장 결석 발생률은 1970년대 후반 3.8%에서 2000년대 후반에는 8.8%로 증가했다고 밝혔습니다. 이러한 유병률의 증가는 더 많은 요관 스텐트 수술을 필요로 하며, 시장 확대의 원동력이 되고 있습니다.
노인은 비뇨기 계통의 문제가 발생하기 쉽기 때문에 전 세계 고령화로 인해 요관 스텐트 수요가 증가하고 있습니다. 세계보건기구(WHO)는 2030년까지 6명 중 1명이 60세 이상이 될 것으로 예측하고 있습니다. 이 수치는 2050년에는 5명 중 1명이 될 것으로 예상됩니다. 통계상으로는 2020년 10억 명에서 2030년 14억 명, 2050년 21억 명으로 증가하게 됩니다. 고령층은 요관 스텐트를 필요로 하는 질환에 걸리기 쉬워 시장 확대에 박차를 가하고 있습니다.
또한, 요관 스텐트 설계 및 재료의 지속적인 발전은 환자 결과를 개선하면서 그 용도를 확장하고 있습니다. 예를 들어, 미국 식품의약국(FDA)은 새로운 요관 스텐트 기술을 적극적으로 승인하고 있습니다. 신장에서 결석 조각을 배출하기 위한 뉴턴 트레이너 요관 카테터는 2019년에 FDA에서 획기적인 장치로 지정되었습니다. 이러한 개선은 요관 스텐트의 용도를 확장하고 시장 확대의 원동력이 되고 있으며, FDA의 CDRH(Center for Devices and Radiological Health)에 따르면 2009년부터 2019년까지 혁신 기기 승인 건수가 25% 증가하여 의료기기, 특히 요관 스텐트의 혁신 추세를 보여주고 있습니다.
약물 용출형 스텐트나 생분해성 스텐트는 더 나은 결과를 가져올 수 있는 획기적인 기술이지만, 특히 자원이 부족한 지역에서는 환자나 의료 전문가들이 접근하기 어려운 고가의 비용으로 인해 접근하기 어려운 경우가 많습니다. 이러한 경제적 부담은 이러한 첨단 솔루션을 채택하려는 의욕을 떨어뜨리고, 결과적으로 동일한 이점을 제공하지 않는 저렴한 대체품에 의존하게 됩니다.
요관 스텐트 삽입 후 문제가 발생할 위험은 또 다른 난제입니다. 환자는 스텐트 이동, 포매, 요로 감염과 같은 합병증이 발생하여 추가 치료가 필요하게 됩니다. 이러한 결과는 환자의 예후에 영향을 미칠 뿐만 아니라 의료비 지출과 자원 사용량을 증가시키기 때문에 의사들은 스텐트 삽입을 첫 번째 치료법으로 제안하는 것을 주저하고 있습니다.
The rising frequency of urological disorders, especially kidney stones, and the use of minimally invasive techniques that improve patient recovery and comfort, are driving the Ureteral Stents Market forward. According to the analyst from Verified Market Research, the Ureteral Stents Market is estimated to reach a valuation of USD 843.74 Million over the forecast subjugating around USD 548.54 Million valued in 2024.
Technological improvements in stent materials and designs, particularly flexible and biocompatible choices, are driving up market demand. It enables the market to grow at a CAGR of 6.1% from 2026 to 2032.
Ureteral Stents Market: Definition/ Overview
A ureteral stent is a thin, flexible tube put into the ureter to aid in the drainage of urine from the kidney to the bladder, especially when normal urine flow is impeded. These stents are widely used to treat kidney stones, ureteral obstructions caused by tumors or strictures, and post-surgical blockages due to swelling or tissue repair. Ureteral stents are an important component in urological therapies because they maintain the ureter open and assist ensure optimal kidney function while also alleviating symptoms associated with urinary obstructions.
The increased occurrence of kidney stones is a major driver of the Ureteral Stents Market. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that kidney stones affect approximately 11% of men and 9% of women in the United States. The NIDDK also notes that the incidence of kidney stones in the United States has risen from 3.8% in the late 1970s to 8.8% in the late 2000s. This increasing prevalence needs more ureteral stent surgeries, which drives market expansion.
The global aging population is driving up demand for ureteral stents, as older persons are more prone to urological problems. The World Health Organization (WHO) predicts that by 2030, one in every six persons will be 60 or older. This number is predicted to rise to one in five by 2050. In statistics, this represents a rise from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. The elderly population is more vulnerable to disorders that necessitate ureteral stents, fueling market expansion.
Furthermore, continuous advancements in ureteral stent design and materials are broadening their uses while improving patient outcomes. For example, the United States Food and Drug Administration (FDA) has been actively approving novel ureteral stent technology. The Newton-Drainer Ureteral Catheter, which is meant to drain stone fragments from the kidney, was designated a Breakthrough Device by the FDA in 2019. Such improvements are expanding the use of ureteral stents and driving market expansion. According to the FDA's Center for Devices and Radiological Health (CDRH), the number of innovative device approvals increased by 25% between 2009 and 2019, demonstrating a trend toward innovation in medical devices, particularly ureteral stents.
Drug-eluting and biodegradable stents are examples of breakthroughs that hold out the potential for better outcomes, but their high cost puts patients and healthcare professionals out of reach, especially in areas with few resources. This financial burden discourages the adoption of these sophisticated solutions, resulting in a reliance on less expensive alternatives that do not provide the same benefits.
The risk of problems following the placing of a ureteral stent presents another difficulty. Patients develop complications such as stent migration, encrustation, and urinary tract infections, requiring extra medical treatments. These consequences not only have an impact on patient outcomes but also raise healthcare expenditures and resource use, making doctors hesitant to propose stenting as a first-line treatment option.
According to VMR analysis, the double pigtail stent segment is estimated to hold the largest market share during the forecast period due to its high biocompatibility, which reduces the chance of unpleasant reactions and problems like infection or tissue irritation. This characteristic makes double pigtail stents the favored option among healthcare professionals, resulting in improved patient outcomes and higher satisfaction rates. Their design enables excellent drainage while decreasing the possibility of encrustation, which increases their attractiveness in clinical settings.
Double pigtail stents' flexibility and simplicity of insertion are also significant factors. Their unique form allows for smoother installation using less invasive techniques, making them easier to manage during treatments. This ease of use not only increases procedural efficiency but also reduces patient discomfort, prompting more healthcare practitioners to employ them for a variety of urological procedures.
Furthermore, the increasing prevalence of urological problems, such as kidney stones and urinary tract blockages, is driving demand for double pigtail stents. As these problems become more widespread, particularly in older populations, healthcare providers rely more on these stents to properly address urinary issues. The increasing prevalence of such illnesses confirms the market dominance of double pigtail stents, which are best adapted to resolving these issues.
The kidney stone segment is estimated to dominate the Ureteral Stents Market during the forecast period due to the high occurrence of kidney stones. Kidney stones impact a large proportion of the global population, creating a growing demand for effective treatment alternatives. Ureteral stents are frequently utilized to relieve obstruction produced by these stones, maintaining correct urine flow and minimizing accompanying pain, emphasizing their critical role in addressing this problem.
Technological developments in stent design are also important for segment growth. Drug-eluting and biodegradable stents are examples of innovations that improve kidney stone treatment effectiveness, patient outcomes, and comfort. These developments not only make it easier to pass stones, but they also reduce complications, leading healthcare practitioners to select ureteral stents as the preferred technique for managing kidney stones.
Furthermore, the growing knowledge and accessibility of healthcare services help to drive the growth of the kidney stones segment. As more patients seek medical assistance for urological disorders, understanding of kidney stone management has grown. This trend promotes timely treatments with ureteral stents, consolidating their position as the preferred method for treating kidney stone-related blockages.
According to VMR analyst, North America is estimated to dominate the Ureteral Stents Market during the forecast period. Urological problems are common in North America, especially in the United States, and are frequently treated using ureteral stents. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), around 11% of men and 6% of women in the United States will have kidney stones at some point in their life. Also, the American Urological Association says that benign prostatic hyperplasia (BPH) affects approximately 50% of men aged 51 to 60 and up to 90% of men over the age of 80, with many requiring ureteral stents as part of their treatment.
Furthermore, the expanding geriatric population in North America is a significant driver of the Ureteral Stents Market, as older persons are more prone to urological problems. According to the United States Census Bureau, by 2030, all baby boomers will be above the age of 65, increasing the number of the elderly population to one in every five individuals. Specifically, the number of Americans aged 65 and over is expected to increase from 52 million in 2018 to 95 million by 2060. This demographic trend is projected to boost demand for urological procedures, such as ureteral stents.
The Asia Pacific region is estimated to exhibit the highest growth within the Ureteral Stents Market during the forecast period. The Asia Pacific region is experiencing considerable growth in the older population, which is particularly vulnerable to urological illnesses that require ureteral stents. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's elder population (aged 65 and more) is predicted to more than double from 535 million in 2015 to around 1.3 billion by 2050. In countries such as Japan, the proportion of people aged 65 and more is expected to reach 38% by 2050. This demographic trend is expected to increase demand for ureteral stents and other urological treatments.
Furthermore, the Asia Pacific region is experiencing an increase in urological problems, particularly kidney stones. According to research published in the Asian Journal of Urology, the prevalence of kidney stone illness in China has risen from 4% in the 1980s to 6.4% in the 2000s. According to India's Department of Health & Family Welfare's Annual Report 2020-2021, urolithiasis (kidney stones) is growing more common, with a prevalence rate of 12% in the adult population. This increased disease burden is likely to drive up demand for ureteral stents in the region.
The Ureteral Stents Market has a broad set of participants, including both large global organizations and smaller, specialized firms. This fragmentation encourages innovation, as businesses focus more on developing new stent technologies, such as drug-eluting and biodegradable choices, to improve patient outcomes and satisfaction.
Some of the prominent players operating in the Ureteral Stents Market include:
Boston Scientific Corporation, Coloplast Ltd., Allium Medical Solutions Ltd., Becton, Dickinson and Company, Cook Group Incorporated, Braun Melsungen AG, Bard, Teleflex Incorporated, Olympus Corporation, and Biomerics.
In May 2022, University Hospitals invented a novel stent developed by Ureteral Stent Co. Lee Ponsky, MD, and obtained FDA Clearance. Ureteral stents facilitate urine flow from the kidney to the bladder, preventing kidney damage caused by kidney stones, strictures, or ureter edema.
In April 2022, Boston Scientific received a bronze Edison Award in the Science & Medical category for its Tria Ureteral Stent. This stent is the first to use proprietary surface technology to prevent the accumulation of calcium and magnesium salt deposits in urine.